Anti-MDA5 Antibody-positive Clinically Amyopathic Dermatomyositis with Rapidly Progressing Interstitial Lung Disease Successfully Treated by Initiation of Combined Immunosuppressive Therapy Plus Plasma Exchange and Subsequently Switching Tacrolimus to Tofacitinib

Intern Med. 2024 Sep 15;63(18):2571-2578. doi: 10.2169/internalmedicine.2915-23. Epub 2024 Feb 12.

Abstract

A 36-year-old man with inverse Gottron's sign was admitted for clinically amyopathic dermatomyositis (CADM) with rapidly progressive interstitial lung disease (RP-ILD). Early addition of plasma exchange (PE) to triple therapy improved severe respiratory failure and transiently decreased serum ferritin levels and anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5 Ab) titers. Furthermore, switching from tacrolimus to tofacitinib resulted in disease remission. Recognition of the inverse Gottron's sign may allow for the earlier diagnosis of anti-MDA5 Ab-positive dermatomyositis, and early addition of PE to triple therapy and administration of tofacitinib in refractory cases may be effective for anti-MDA5 Ab-positive CADM with RP-ILD under life-threatening conditions.

Keywords: anti-MDA5 antibody; clinically amyopathic dermatomyositis; interstitial lung disease; inverse Gottron's sign; plasma exchange; tofacitinib.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Autoantibodies / blood
  • Combined Modality Therapy
  • Dermatomyositis* / blood
  • Dermatomyositis* / complications
  • Dermatomyositis* / diagnosis
  • Dermatomyositis* / drug therapy
  • Dermatomyositis* / immunology
  • Disease Progression
  • Humans
  • Immunosuppressive Agents* / therapeutic use
  • Interferon-Induced Helicase, IFIH1* / immunology
  • Lung Diseases, Interstitial* / complications
  • Lung Diseases, Interstitial* / drug therapy
  • Lung Diseases, Interstitial* / immunology
  • Male
  • Piperidines* / administration & dosage
  • Piperidines* / therapeutic use
  • Plasma Exchange*
  • Pyrimidines* / therapeutic use
  • Pyrroles / therapeutic use
  • Tacrolimus* / administration & dosage
  • Tacrolimus* / therapeutic use
  • Treatment Outcome

Substances

  • tofacitinib
  • Interferon-Induced Helicase, IFIH1
  • Pyrimidines
  • IFIH1 protein, human
  • Immunosuppressive Agents
  • Piperidines
  • Tacrolimus
  • Autoantibodies
  • Pyrroles

Supplementary concepts

  • Amyopathic dermatomyositis